Caspofungin Acetate Injection shortage
To Be Discontinued 3 presentations · 2 manufacturers · first FDA posting 2026-01-12 · last update 2026-06-30
Manufacturers: Fresenius Kabi USA, LLC, Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.)
Stated reasons (per FDA): Not stated
Presentations
| Presentation | Manufacturer | Status | Reason | Notes (FDA) | Dates |
|---|---|---|---|---|---|
| Caspofungin Acetate, Injection, 7 mg/1 mL (NDC 63323-358-10) | Fresenius Kabi USA, LLC | To Be Discontinued | — | Discontinuation of the manufacture of the drug | Posted 01/12/2026 Updated 01/12/2026 Discontinued 01/12/2026 |
| Caspofungin Acetate, Injection, 5 mg/1 mL (NDC 0781-3421-94) | Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) | To Be Discontinued | — | Marketed by Sandoz, Inc.; Discontinuation of the manufacture of the drug | Posted 06/30/2026 Updated 06/30/2026 Discontinued 06/30/2026 |
| Caspofungin Acetate, Injection, 7 mg/1 mL (NDC 0781-3423-94) | Jiangsu Hengrui Pharmaceuticals Co. (US Agent eVenus Pharmaceutical Laboratories, Inc.) | To Be Discontinued | — | Marketed by Sandoz, Inc.; Discontinuation of the manufacture of the drug | Posted 06/30/2026 Updated 06/30/2026 Discontinued 06/30/2026 |
Get the weekly shortage roundup: a free email of FDA shortage changes (open form)